Advocate, Connect, Promote, Inform | |
It is our mission to secure Indiana’s position as a global leader in life sciences by advocating, connecting, promoting, and delivering tangible benefits on behalf of our diverse corporate members. | |
Thank you to everyone who joined us for the Launch Party! | |
|
The Indiana Health Industry Forum is officially the IN Life Sciences Association! Thank you to everyone who joined us on October 9th for our Launch Party! It was great to see all the PURPLE! We would like to thank our sponsors for their incredible support: PhRMA, BIO, AdvaMed, Indiana University-Indianapolis, BSA LifeStructures, The P3 Acceleration Group, and Quality Connection. Thanks, too, to our volunteers for the evening, Katie Scott and Badma Rajan! | |
Be sure to check out our Member Directory featuring company descriptions and an alphabetical listing. | |
|
GxPartners provides a comprehensive range of Quality, Regulatory, and Validation services in the Medical Device, Pharmaceutical, and Biotech Industries.
We are a full-service Life Sciences staffing and consulting organization focused on providing solutions to meet our Clients’ goals while making sustainability top-of-mind. Directory Link
| |
|
Valkit employs automation and contextual AI to maximize quality and productivity in validation teams, while dramatically reducing CQV, CSV & CSA timelines and cost Directory Link
| |
NOTE: Valkit.ai CEO, Hugh Devine, will be in Indiana from Scotland on November 20th. If you would like to request a meeting to learn more about Valkit, please let us know! | |
|
We are strategic communicators offering concierge marketing, PR and media relations services. We're a small agency that gets big results. We understand that when it comes to marketing and communications, one size doesn't fit all. That's why we provide only the services your business needs at an affordable price. Don't know what you need? We provide a free gap analysis to identify where and when it makes the most sense to spend your marketing dollars. Directory Link
| |
|
Vasculonics is a biotech specializing in organ protection strategies following insult from acute or chronic diseases, or trauma. The company is developing VN-1032, an oral tablet which is disease modifying for pulmonary arterial hypertension, chronic kidney disease, traumatic brain injury and vascular dementia, an extracorporeal medical device VN-901 for acute trauma and diseases with both hospital and military medicine applications. This includes sepsis, acute kidney disease, heart attack, and blast injury. More... Directory Link
| |
|
We’re building the most patient-friendly way to access clinical trials. Our team @ Power believes that every patient deserves the chance to participate in a life changing clinical trial. Directory Link
| |
|
Continuity Pharma is a spin-out from the lab of Prof. David H. Thompson at Purdue University. We leverage innovative chemistry and flow technology to improve quality, safety and sustainability in the pharmaceutical industry by developing advanced manufacturing processes for small molecule active pharmaceutical ingredients (API). Using our technology, our customers can drive down costs, and bring high-quality products to market faster and cheaper. Directory Link
| |
|
At EchoTech, we've developed a comprehensive autonomous vision platform. Our initial product, Magic Mode, is designed to enhance the lives of powered wheelchair users. We believe everyone deserves the freedom and confidence to explore their surroundings without limitations, and that's precisely what Magic Mode delivers. Directory Link
| |
|
HabitHalo was founded by a former vaper who struggled with control and realized existing methods needed to be updated and made specifically for vapers. HabitHalo is the result of this collective dedication, packaged conveniently in an app that personalizes to each vaper and automates restrictions through our vape compatible hardware device. Directory Link
| |
The Indiana Health Industry Forum provides guidance and leadership on public policy issues that contribute to innovation in the health science sector, deliver therapies to patients in need, and further the development and growth of our member companies. IHIF works at the federal and state level and partners with several other organizations and groups to support specific initiatives and legislation.
| |
|
What We're Following at Home and on the Hill
-
Find your legislators and keep up with our advocacy efforts - here
-
Policy Forum Members: Session Updates and Bill Tracker (2025 Session Coming Soon)
- Organization Day is November 21!
| |
|
Actions:
- PULSE campaign highlights changes to pre-merger notification rules in POLITICO PULSE.
- IN Life Sciences Association Issues Statement on HSR Pre-Merger Notification Rules (below)
- Joined letter thanking Congressmen Bucshon and Pence for their response regarding the IRA’s impact on Medicare premiums and CMS’s plans to handle premium increases.
- Signed on to new letter supporting reauthorization of Pandemic All Health Preparedness Act (PAHPA) before the end of the year.
- Click here to see all of the topics and issues we are monitoring
| |
|
PULSE campaign highlight in POLITICO PULSE (10/22/24)
MERGER BURDEN SHIFT? The Federal Trade Commission recently finalized new rules that expand requirements for companies across sectors to notify the agency and the Justice Department of significant mergers in a move that could have a considerable impact on health care companies, Ben reports.
When they go into effect in mid-January, the rules seek to dramatically increase the information companies must provide about mergers. They’ll apply to hospitals, pharmaceutical companies, tech firms and providers in deals over a certain financial threshold.
Transparency vs. innovation: The rules are a game-changer that supporters say will require companies to be more transparent and take the burden off regulators in trying to prevent illegal mergers and acquisitions. Opponents argue they’ll stifle innovation. Companies will have to disclose the reasoning behind the transactions and any product overlaps or vertical ties, including providing additional documentation about transactions or face potential civil penalties. Vertical mergers occur between companies at different levels of supply chains.
Read Full Article
| |
IN Life Sciences Association Statement on Hart-Scott-Rodino Rules | |
In response to the final Hart-Scott-Rodino (HSR) premerger notification rules issued late yesterday by the Federal Trade Commission (FTC), the Indiana Life Sciences Association released the following statement:
“As an organization which works to secure Indiana’s position as a global leader in life sciences, we are concerned about the implications of the final HSR rules as issued by the Federal Trade Commission. The increased premerger reporting requirements will inflict substantial costs on our state’s life science industry, which drives $95 billion to Indiana’s economy and provides 67,000 jobs statewide. We are particularly concerned that small and early-stage biopharmaceutical companies will bear the brunt of these costs, which may be insurmountable as an estimated 80% of these companies operate without a profit. We urge our federal representatives to support a return to balanced and bipartisan public policies that are supportive of Indiana’s life sciences ecosystem, which requires pro-competitive mergers in order to continue pushing the boundaries of innovation, collaboration and growth.”
| |
Exclusive: Sen. Todd Young on biosecurity, National Security Commission on Emerging Biotechnology (NSCEB)
Sen. Todd Young (R-IN) was recently named Chair of the National Security Commission on Emerging Biotechnology (NSCEB), established by Congress to recommend policy on biotech and national security. Bio.News spoke to him in an exclusive interview about the work of the commission, the BIOSECURE Act and PASTEUR Act, and more.
Read Here
| |  |
|
New Study Reveals Patients are Unlikely to See Out-of-Pocket Drug Savings from IRA Price Controls
New research from the IQVIA Institute for Human Data Science and We Work for Health further confirms what many experts have already warned: The Inflation Reduction Act’s (IRA) price controls on prescription drugs will not achieve their stated goal of consistently reducing patient out-of-pocket costs. Rather, several unintended consequences will reduce choices for patients, raise costs for many and threaten the development of future therapies.
Read the study here.
| | |
That’s a wrap: 5 takeaways from The Medtech Conference
The conference — Advamed’s largest — featured an appearance by the device center’s new acting director and sessions on AI, clinical trial diversity and the FDA’s contentious LDT rule.
Read More
| | |
Public policy & advocacy
Working alongside health policy specialists, we guide decision-makers at all tiers of government by offering policy suggestions that incorporate technology in health.
| | |
|
Don't Miss This Member Benefit!!
Access to capital is the #1 issue we hear from our members, so we are offering you a NEW member-only service to help you access non-dilutive funding from the government. By teaming up with G2G Consulting, which has secured over $531 million in government funding since 2007, you will receive a monthly report on life sciences grants and a monthly webinar with government funding experts to ask questions and gain insights on how to obtain funding. This Government Biosciences Grant Report or GBG Report is updated and published monthly with all life sciences opportunities spanning from NIH to BARDA to DoD to USDA to NSF to ARPA-H included.
Learn More
Not an IN Life Sciences Association Member? Sign up here to access this benefit and more!
| |
News From Our Members and Around the Industry | |
As a member benefit, we are pleased to share and highlight member company news! Please send press releases to info@INLifeSciences.org | |
|
Need help telling your story?
We are able to provide access to contract/custom press release and writing services. (Fee for service). Inquiries welcome - click here
| |
|
Helix BioStructures Named Drug Discovery Services Company of The Year-2024 by Life Sciences Review
HELIX BIOSTRUCTURES: Drug Discovery Services Company of the Year, 2024!
"Recognized as a thought leader in the industry, Helix BioStructures is a leading contract research organization (CRO) that specializes in early-stage drug discovery. At the heart of Helix’s expertise lies structure-based drug design—a sophisticated technique that leverages high-resolution, three-dimensional structures of recombinant proteins to drive the development of innovative drug molecules."
Read
| |
|
Vasculonics, Inc. Awarded a $2.2 Million Dollar Phase II SBIR Grant to Develop a First-In-Class Disease Modifying Therapy for Pulmonary Arterial Hypertension
Vasculonics, Inc., an emerging biopharma company developing therapies to treat fibrotic disease, today announced that they are the recipient of a Phase II SBIR grant from the National Institutes of Health - National Heart Lung and Blood Institute (NHLBI) for $2.2 million. The Phase II award is to continue the development of VN-1032, Vasculonics’ first-in-class, orally administered therapy for pulmonary arterial hypertension (PAH) targeting the aryl hydrocarbon receptor (AhR) selectively.
Read Full Release
| |
|
Barnes & Thornburg Launches 2025 Healthcare Compliance Outlook
Emerging Cybersecurity, Data, and Regulatory Risk in the Age of AI
The majority of healthcare and life sciences professionals surveyed feel stretched thin as they navigate complex regulations and newer risks, including mounting cyberattacks, the rapid adoption of artificial intelligence (AI), and increased scrutiny of healthcare mergers and acquisitions.
Some of the key findings include:
· Only 31 percent of healthcare compliance and risk leaders feel “very prepared” to meet future compliance and risk challenges; less than half (42 percent) are very confident about maintaining high quality of care in light of compliance and risk issues
· More than half (53 percent) report resource constraints in program areas like budget, staffing and technology; 56 percent expect to face more resource limitations in the next year
· More than half (54 percent) of organizations are already seeking private equity backing or considering it
Download the Report
| |
|
Cushman & Wakefield - NOW AVAILABLE: U.S. Life Sciences Fit Out Guide
The 2025 U.S. Life Sciences Fit Out Cost Guide is an essential tool for corporate real estate decision-makers in the Life Sciences space. It provides a better understanding of costs and trends, aiding in capital planning and development of relocation budgets.
The U.S. Life Sciences Fit Out Cost Guide provides life and technology sciences clients with the data and intelligence they need to make the right real estate decisions in a complex environment. This Guide covers five lab, two cGMP, warehouse and office facility types across the six major U.S. life sciences markets.
For those focusing on the Indianapolis market, you'll find valuable insights drawn from the Raleigh-Durham data, which shares a comparable RSMeans City Cost Index.
Access the Guide
| |
|
SpectronRx moves forward with European facility plans
Indianapolis-based SpectronRx announced Thursday that the radiopharmaceutical company has executed a binding agreement with a Belgian company to manufacture a promising cancer therapy for patients in Europe. The agreement with the Belgian Nuclear Research Center initially will focus on the labeling of Actinium-225-based radiopharmaceuticals.
More
| |
Regenerative biomaterial innovator GeniPhys awarded NSF SBIR Phase IIB grant
GeniPhys, a preclinical-stage company developing regenerative collagen polymeric biomaterials for soft tissue restoration, has been awarded a $500,000 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase IIB supplemental funding grant to support regulatory and commercial readiness of its flagship product, Collymer Self-Assembling Scaffold (SAS). The Phase IIB grant supplements a nearly $1 million NSF SBIR Phase II grant awarded to GeniPhys in 2022 and will support completion of manufacturing scalability and necessary testing to achieve 510(k) clearance of Collymer SAS for the wound care market.
Read More
| |
|
Catherine Peachey Fund in Support of Breast Cancer Research Opens Sponsor Options for 2025 Wine Tasting with Peachey Event
Contact Stephanie Lesher for more information or visit www.peacheyfund.com
| |
With BIO Business Solutions (BBS), Indiana Life Sciences Association members are eligible for discounts and savings on a wide variety of products and services geared towards life sciences companies and general business needs. From lab supplies, waste removal and insurance, to office supplies and credit cards, there is something here for every company. Explore your options and enjoy the benefits of being an IHIF member! | |
BIO Business Solutions - Special Discounts for Members | |
|
Featured Program
Please share this with someone in your company who would find this helpful
| BIO Business Solutions provides cost-savings offers to eligible IN Life Sciences Association Members. To learn more about the programs and services available, please click here. Not a member? Join today! | |
|
The Nikon BioImaging Lab (NBIL) provides contract research services for microscope-based imaging and analysis. Capabilities include not only access to cutting-edge microscopy instrumentation and software, but also the services of expert biologists and microscopists, who are available to provide quality cell culture, sample preparation, data acquisition, and data analysis services.
All work is charged on a simple per hour basis to ensure accessibility for all types of customers in biotech, pharma, and larger research communities.
.
Limited Time Promotion
Nikon is eager to help accelerate your research! That's why for a limited time, we're offering a free consultation and up to four hours of microscope-based imaging. Fill out this form to learn more.
| |
Member Savings on Imaging Services
7% exclusive discount on Nikon BioImaging Lab services, such as:
- Full-service imaging
- Consumable supplies
- Lab assisted equipment use
- Lab occupancy fee
Additional Benefits
- Industry-leading microscope systems and software solutions for imaging of wide ranges of specimens from single cells to complex microphysiological systems.
- Consistent, bias-free data quality, professional image processing.
- Streamlined, automated and AI-supported high-content imaging and analysis using Nikon’s NIS Elements software.
- Expertise in experimental design and execution and project consulting with our team of biologists and microscopy imaging professionals.
| |
Life Science Executives, On Demand
BiotechExec provides life science companies with the strategic business solutions and talent needed to bring their life-changing, life-saving products to the market.
TIP: Will your company be participating in trade shows or partnering events this year? Investors and strategics generally accept meetings with people they know before they take meetings with people they don’t know. Consider adding an experienced Business Development exec from BiotechExec with their established contacts and industry relationships. Leveraging their network can help your company get broad visibility and establish meaningful connections, to optimize the event experience and investment in time and cost.
Learn More! Contact: Steve Joseph, VP Business Development, Biotech Exec
https://biotechexec.com/
| |
-
G2G Consulting Monthly Non-Dilutive Gov't Funding Webinar - November 21, Noon - Register
- Scotland Extravaganza 2025 Announced - May 5-11, 2025
- Valkit.ai Visit to Indiana November 20. See New Member Section for details.
-
Dec.13 - IU Kelley School of Business - IN Life Sciences Collaboration Conference- Changes in the Healthcare Ecosystem Register/More Information
|  | |
Tuesday, November 19, 2024
11:30 am - 1:00 pm
Location: Barnes & Thornburg LLP
11 S. Meridian Street, Indianapolis, IN 46204
IU-Indianapolis Life Sciences Strategic Plan Update and Introductions
IU-Indianapolis is well on its way to becoming a Tier 1 research university. Following a detailed strategic plan announced one year ago, the university pledged to invest more than $250 million to advance scientific discoveries aimed at curing and treating diseases and improving human health, while cementing Indiana’s position as a global leader in life sciences and biotechnology innovation.
Today, the campus has put in place two new interdisciplinary research centers, supported by a high-tech research lab with equipment and capabilities open to industry partners. Please join us as we get to know the new leadership team, hear their visions for their respective areas, and learn what’s next for the IU-Indianapolis campus and community!
There will not be a Zoom option for this session.
Moderator –Kristin Jones, President and CEO, Indiana Life Sciences Association
Panel:
-
Phaedra Corso, Ph.D., Associate Vice President and Vice Chancellor for Research, Indiana University
- James Lin, Ph.D., Executive Director, Convergent Bioscience and Technology Institute (CBATI), Indiana University Indianapolis
- Stephen Boehm, Ph.D., Executive Director, IU Institute for Human Health and Wellbeing, Indiana University Indianapolis
- Mangilal Agarwal, Ph.D., Director, Integrated Nanosystems Development Institute, Indiana University Indianapolis
There is no charge to participate.
| |
|
Join the IN Life Sciences Association
Become a Member Today!
| |
|
About Membership
Now is a great time to become a member of the Indiana Life Sciences Association! Join your voice to over 200 current member companies to impact the strategic direction of Indiana's life science sector.
Membership offers a number of solutions:
- Promote your business, locally, nationally, and globally.
- Support the industry in the state and contribute directly to its growth and direction.
- Find others who share your interests and build your business network.
- Lend your voice to public policies that support innovation.
- Increase your buying power and directly impact your bottom line with significant savings and discount programs exclusively for members.
To complete a membership application, click here.
| | | | |
